^
    2d
    Evaluate the Safety and Clinical Activity of HH2853 (clinicaltrials.gov)
    P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1)
    |
    ARID1A mutation • EZH2 mutation
    |
    HH2853
    2d
    Mandolin: A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (clinicaltrials.gov)
    P2, N=0, Withdrawn, Epizyme, Inc. | N=55 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat)
    2d
    SIDNEY: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Enterome | N=60 --> 80 | Trial completion date: May 2032 --> May 2034 | Trial primary completion date: May 2026 --> May 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • EO2463
    2d
    POTENTIAL-M: NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=9, Recruiting, NOBO Medicine | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Dec 2025
    Enrollment open • Trial initiation date
    |
    poseltinib (HM71224)
    2d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    3d
    Application of tyrosine kinase-like orphan receptor 1 (ROR1) targeted imaging based on positron emission tomography (PET) in malignant tumors (ChiCTR2600116180)
    P=N/A, N=20, Recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    3d
    A prospective, single-arm, multicenter clinical study of zanubrutinib in combination with obinutuzumab and low-dose bendamustine as first-line treatment for high-risk (FLIPI-2 >= 3) follicular lymphoma patients. (ChiCTR2500114118)
    P4, N=25, Not yet recruiting, People‘s Hospital of Xinjiang Uygur Autonomous Region; People‘s Hospital of Xinjiang Uygur Autonomous Region
    New P4 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine
    3d
    A single-Arm, Open-Label Ib/II Study of Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma(PTCL) (ChiCTR2500111610)
    P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    Duoenda (mitoxantrone liposomal) • Enshuxing (enlonstobart)
    3d
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=3, Completed, Peking University | Recruiting --> Completed | N=18 --> 3
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    4d
    Histological and Immunohistochemical Characterization of a Histiocytic Sarcoma Associated With a Follicular Lymphoma in a Ring-tailed Lemur (Lemur catta). (PubMed, Vet Med Sci)
    The histomorphologic and immunohistochemical features of the histiocytic sarcoma in this Lemur catta were characteristic of this condition in other species. This report documents the first case of histiocytic sarcoma in Lemur catta, providing novel histopathological and immunohistochemical insights of this condition in prosimians.
    Journal
    |
    PAX5 (Paired Box 5) • IRF4 (Interferon regulatory factor 4)
    5d
    Diagnostic challenges in pediatric lymphomas (PubMed, Pathologie (Heidelb))
    Their diagnosis requires careful consideration to accurately distinguish rare indolent entities, recently defined large B‑cell lymphomas, and reactive mimics. Recent classifications, including the newly introduced WHO Classification of Pediatric Tumors, increasingly reflect these unique aspects.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    5d
    Primary Cutaneous Peripheral T-Cell Lymphoma With TFH Phenotype With Divergent Clonal B- and Plasma-Cell Populations and DNMT3A Mutation. (PubMed, J Cutan Pathol)
    This case represents a rare pcTFH-PTCL with a persistent T-cell clone coexisting with divergent clonal B- and plasma cell populations. The findings emphasize the role of TFH-derived neoplasms in fostering B-cell expansions and highlight the diagnostic and therapeutic complexity posed by dual-lineage clonality in cutaneous lymphomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)